Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Feb;45(2):171-4; discussion 174-5.
doi: 10.1016/j.eururo.2003.10.007.

A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer

R J Parkinson  1 , M S Simms, P Broome, J E Humphreys, M C Bishop
Affiliations
Clinical Trial

A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer

R J Parkinson et al. Eur Urol. 2004 Feb.

Abstract

Objectives: We have previously reported the ability of D17DT (formerly GnRH-DT) vaccination to produce castrate levels of androgens in men with advanced prostate cancer. This study examines the efficacy and tolerability of 3 and 15 micrograms of D17DT in 12 patients with advanced prostate cancer to establish a dose-response relationship.

Methods: 12 patients received either 3 or 15 micrograms of D17DT as 3 deep intramuscular injections over 6 weeks. Outcome was assessed in terms of physical and biochemical evaluations of clinical progression and antibody titres.

Results: Significant titres of anti-GnRH antibodies were detected in 2 out of 6 subjects who received 15 micrograms of D17DT; suppression of testosterone to castrate levels accompanied by a significant and prolonged reduction in PSA was also demonstrated. No responses were seen following treatment with 3 micrograms of D17DT.

Conclusion: The induction of anti-GnRH antibodies through vaccination with 15 micrograms D17DT can produce and sustain castrate levels of testosterone in men with advanced prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Vaccines for immunological control of fertility.
    Gupta SK, Bansal P. Gupta SK, et al. Reprod Med Biol. 2009 Dec 1;9(2):61-71. doi: 10.1007/s12522-009-0042-9. eCollection 2010 Jun. Reprod Med Biol. 2009. PMID: 29699331 Free PMC article. Review.
  • Versatile virus-like particle carrier for epitope based vaccines.
    Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, Jennings GT, Saudan P, Pumpens P, Bachmann MF. Tissot AC, et al. PLoS One. 2010 Mar 23;5(3):e9809. doi: 10.1371/journal.pone.0009809. PLoS One. 2010. PMID: 20352110 Free PMC article.
  • Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.
    Junco JA, Rodríguez R, Fuentes F, Baladrón I, Castro MD, Calzada L, Valenzuela C, Bover E, Pimentel E, Basulto R, Arteaga N, Cid-Arregui A, Sariol F, González L, Porres-Fong L, Medina M, Rodríguez A, Garay AH, Reyes O, López M, de Quesada L, Alvarez A, Martínez C, Marrero M, Molero G, Guerra A, Rosales P, Capote C, Acosta S, Vela I, Arzuaga L, Campal A, Ruiz E, Rubio E, Cedeño P, Sánchez MC, Cardoso P, Morán R, Fernández Y, Campos M, Touduri H, Bacardi D, Feria I, Ramirez A, Cosme K, Saura PL, Quintana M, Muzio V, Bringas R, Ayala M, Mendoza M, Fernández LE, Carr A, Herrera L, Guillén G. Junco JA, et al. Front Oncol. 2019 Feb 25;9:49. doi: 10.3389/fonc.2019.00049. eCollection 2019. Front Oncol. 2019. PMID: 30859088 Free PMC article.

MeSH terms

LinkOut - more resources